IDH-wild-type

IDH-wild-type predicts individualized survival probabilities for patients with isocitrate dehydrogenase (IDH)-wild-type glioblastoma (GBM) using clinical and molecular prognostic variables.

Key Features:

• Data-Driven Development: Constructed using data from newly diagnosed GBM patients collected between 2007 and 2017 from the Ohio Brain Tumor Study (OBTS) and the University of California San Francisco (UCSF) cohorts.
• Incorporated Variables: Integrates age at diagnosis, sex, extent of resection, concurrent radiation/temozolomide (TMZ) status, Karnofsky Performance Status (KPS), O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and IDH mutation status.
• Advanced Statistical Methods: Employs Cox proportional hazards regression, random survival forests, and recursive partitioning analysis for prognostic modeling.
• Validation Process: Includes internal validation by 10-fold cross-validation and external validation assessed by plotting calibration curves.
• Clinical Utility: Produces individualized survival probability estimates to inform patient counseling and treatment planning for newly diagnosed IDH-wild-type GBM.

Scientific Applications:

• Prognostication: Provides individualized survival estimates for patients with IDH-wild-type GBM incorporating clinical and molecular factors.
• Treatment planning and counseling: Supports clinical decision-making by quantifying survival probabilities relevant to therapeutic strategy selection and patient discussions.

Methodology:

Model development used Cox proportional hazards regression, random survival forests, and recursive partitioning analysis with internal validation by 10-fold cross-validation and external validation via calibration curves.